#USA #San Diego #NIH SBIR Grant #Tempo Therapeutics #MAP Technology

Tempo Therapeutics Receives $2.25 Million Grant

Tempo Therapeutics, Inc., a pioneering company in regenerative medicine, has announced the receipt of a $2.25 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). This grant is set to propel the development of their proprietary Microporous Annealed Particle (MAP™) Wound Matrix, aimed at transforming the management of complex wounds.

A Revolutionary Approach to Wound Healing

The MAP™ technology seeks to revolutionize wound care by promoting the generation of healthy, functional tissue while minimizing the inflammatory responses typically associated with traditional methods. Steven Sands, Chairman of Tempo Therapeutics, emphasized how this essential funding moves the company closer to a milestone that could illustrate MAP as a novel strategy in wound management. The company hopes to illustrate that MAP will significantly improve healing times and patient outcomes while also reducing the overall clinical burden of complex wounds.

Details of the Project

The project, titled MOSAIC II, intends to support a randomized clinical study examining the MAP Wound Matrix's effectiveness in reducing the time required for graft readiness following surgeries for non-melanoma skin cancers. Led by Dr. Stephanie Deshayes, Vice President of Research & Development at Tempo, this study aims to evaluate how MAP technology can address the significant clinical needs associated with difficult wounds that often resist traditional treatments.

Dr. Deshayes remarked, "MAP is designed to accelerate the formation of healthy, vascularized tissue, which is crucial for effective wound healing. By securing this award, we now have the opportunity to assess our approach on more challenging wounds that call for innovative solutions."

Unique Properties of MAP Technology

Traditional wound treatment methods frequently provoke a persistent foreign-body response that can hinder healing. In contrast, MAP technology has been engineered to facilitate the body’s natural regenerative processes, thus allowing for enhanced growth of healthy tissue within complex wounds. This innovative scaffold supports the rapid ingrowth of cells, creating a well-vascularized wound bed that can be readily prepared for subsequent reconstruction or grafting.

Westbrook Weaver, Co-Founder and Chief Technology Officer of Tempo Therapeutics, elaborated on the significance of MAP technology: "The capacity to regenerate tissue within the volume of a complex wound, instead of solely from the margins, has the potential to transform treatment methodologies for challenging wounds."

Positive Preliminary Results and Future Implications

This newly funded study follows Tempo's recent successful completion of a first-in-human randomized controlled multicenter trial examining MAP's effects on full-thickness wounds following Mohs surgery. The initial study revealed that MAP-treated wounds reached a favorable Wound Bed Score approximately 14 days earlier than controls, showcasing the promising potential of this technology to enhance healing without delaying overall closure.

Given these encouraging findings, MOSAIC II aims to investigate whether MAP can expedite the development of a graft-ready wound bed after complex surgical resections. This could lead to significant advancements in wound care therapies and surgical outcomes for patients who currently have limited treatment options.

About Tempo Therapeutics

Tempo Therapeutics is positioned as a clinical-stage company dedicated to developing synthetic biomaterials to promote healthy tissue regeneration. They are harnessing their patented MAP™ technology platform to create advanced products that cater to surgical reconstruction, wound healing, and emerging applications in aesthetic dermatology and regenerative medicine. The company's lead product has already undergone first-in-human clinical trials and is submitted for FDA approval via the De Novo pathway.

This NIH funding will allow Tempo to significantly contribute to innovative healthcare solutions, addressing unmet clinical needs in the realm of wound healing and reconstruction.